Johnson & Johnson: A Buy and Core Holding for the Long Haul (JNJ, $68.35)Thursday, August 9, 2012 · 11:57 am |
|
Quarterly Sales Show That Both Provenge and Zytiga Are Doing Very Well (DNDN, $13.58)Wednesday, February 1, 2012 · 10:36 am |
|
FDA Advisory Committee Goes Against FDA and Recommends Approval of XareltoFriday, September 9, 2011 · 9:25 am |
|
Xarelto Could Be Another Blockbuster (JNJ, $66.64)Friday, July 22, 2011 · 10:48 am |
|
Second Quarter Report Was Modestly Disappointing But New Pharmaceutical Products are the Key to the Investment Outlook (JNJ, $66.26)Wednesday, July 20, 2011 · 9:58 am |
|
Initial Buy Recommendation (JNJ, $62.69)Friday, June 3, 2011 · 3:52 pm |
|
Telaprevir Has Significant Therapeutic and Blockbuster Sales Potential for Hepatitis C (JNJ, $64.95)Monday, May 16, 2011 · 2:57 pm |
|
Abiraterone is Significant Advance in Prostate Cancer Treatment (JNJ, $64.11)Monday, May 16, 2011 · 2:05 pm |
|
Hopes for Rivaroxaban Are Dashed (JNJ, $65.00)Saturday, January 8, 2011 · 1:25 pm |
|
|
There are 9 reports on file. |
